Heidelberg, July 22nd, 2007 - SYGNIS Pharma AG has successfully completed the clinical phase IIa-study (AXIS) in stroke. AXIS was a multicenter, doubleblind, placebo-controlled dose escalation study. The comprehensive analysis of the study data showed that the primary and secondary endpoints have been achieved and that the use of AX200 in stroke patients can be considered to be safe.
